Device: LetsGetChecked Coronavirus (COVID-19) Test
EUA Number: EUA201043
Company: LetsGetChecked, Inc.
Indication: This test is authorized for the following indications for use:

A direct to consumer product for testing of anterior nasal swab specimens self-collected at home using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit by any individuals, age 18 years and older (self-collected), 12 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance), including individuals without symptoms or other reasons to suspect COVID-19.

Qualitative detection of nucleic acid from SARS-CoV-2 in pooled samples containing up to 5 anterior nasal swab specimens per pool that were collected in individual vials containing transport media using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit from any individual (age 2 years and older), including individuals without symptoms or other reasons to suspect COVID-19.

Emergency use of this test is limited to the authorized laboratory.

Authorized Laboratory: Testing is limited to the LetsGetChecked, Inc. laboratory (PrivaPath Labs d.b.a. LetsGetChecked Labs) which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, and meets the requirements to perform high complexity tests.

Dear Ms. Cupp:

On May 28, 2020, based on a request from PrivaPath Diagnostics, Inc. (“PrivaPath”), the Food and Drug Administration (FDA) issued a letter authorizing the emergency use of
LetsGetChecked Coronavirus (COVID-19) Test for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal swab specimens self-collected by individuals at home, using the LetsGetChecked COVID-19 Home Collection Kit, when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire (based on current testing guidelines), pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). Testing was limited to PrivaPath Labs d.b.a. LGC Labs certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests. Subsequently, on July 6, 2020, and October 23, 2020, FDA granted PrivaPath’s request to update the authorized labeling.1,2 Based on your requests, the May 28, 2020, letter has been revised and reissued by FDA on August 14, 2020, February 19, 2021, March 18, 2021 and May 19, 2021.3,4,5,6

1 On July 6, 2020, your request was granted to update the authorized labeling of your product to add the Hologic Aptima SARS-CoV-2 Assay (Panther System) per the instructions (without modification), in addition, to an RNaseP gene RT-PCR as an alternative assay for use in the PrivaPath workflow for processing nasal swab specimens self-collected by individuals at home.

2 On October 23, 2020, your request was granted via email to update the EUA Summary of your product to add the results of testing the FDA SARS-CoV-2 Reference Panel Testing. FDA posted the update to the web on October 28, 2020.

3 On August 14, 2020, the revisions to the May 28, 2020, letter and authorized labeling included: (1) extending the specimen shipping stability claim in the Standard Operating Procedure: COVID-19 Testing Specimen Receiving, Storage, and Processing and the EUA Summary, (2) removal of the RNaseP internal control requirement for self-collected samples, (3) updating labeling documents to remove the requirement to run the RNaseP internal control, (4) adding conditions of authorization specific to removal of the RNaseP internal control, (5) updating the healthcare provider and patient fact sheets to include some additional warnings/precautions around the absence of an RNaseP internal control when self-collected specimens are tested, (6) updating the PrivaPath website at FDAs request to include some considerations and warnings prior to ordering the LetsGetChecked COVID-19 Home Collection Kit, and (7) minor updates to the intended use to include “that meets the requirements” to perform high complexity tests when describing the authorized laboratory.

4 On February 19, 2021, the revisions to the August 14, 2020, letter and authorized labeling included: (1) updating the company name from PrivaPath Diagnostics, Inc. to LetsGetChecked Inc., (2) updating “LetsGetChecked COVID-19 Home Collection Kit” to “LetsGetChecked Coronavirus (COVID-19) Home Collection Kit” and clarifying “LGC Labs” as “LetsGetChecked Labs” in the laboratory name, (3) updating the intended use to “nucleic acid from the SARS-CoV-2 in anterior nasal swab specimens self-collected by any individuals at home, using the LetsGet Checked Coronavirus (COVID-19) Home Collection Kit, including for testing individuals without symptoms or other reasons to suspect COVID-19 when ordered by a healthcare provider,” (4) removal of the Hologic Panther Fusion SARS-CoV-2 assay from the workflow, (5) removal of the questionnaire to determine eligibility for the testing, (6) updating the performance data to include winter shipping stability, (7) removal of Condition X. (from the August 14, 2020, letter) which was fulfilled, (8) updating the conditions of authorization to add a post-authorization clinical study and reflect language used in more recent authorizations (9) adding limitation related to performance with circulating variants, and (10) updating the fact sheets for healthcare provider (including with information related to performance with circulating variants) and patient.

5 On March 18, 2021, the revisions to the February 19, 2021, letter and authorized labeling included: (1) updating the intended use with DTC language, (2) removal of “Prescription Use Only” language from authorized labeling, (3) updating the “Fact sheet for patients” to “Fact sheet for individuals” for inclusion in the LetsGetChecked COVID-19 Home Collection Kit, (4) addition of clinical performance data of the LetsGetChecked Coronavirus (COVID-19) Test in asymptomatic individuals, and (5) removal of Condition U. (from the February 19, 2021, letter) which was fulfilled and addition of Condition M.

6 On May 19, 2021, the revisions to the March 18, 2021, letter and authorized labeling included: (1) update to the intended use to indicate testing of individual anterior nasal swab specimens from individuals age 18 years and older (self-collected), 12 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance), (2) addition of limitation statement stating the lack of evaluation with specimens collected from individuals 18 years and older by an adult in the home, and (3) updates to the Healthcare Provider and Individual Fact Sheets to reflect language used in more recent authorizations.
On August 12, 2021, you requested further revisions to your Emergency Use Authorization (EUA). Based on this request, and having concluded that revising the May 19, 2021, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the May 19, 2021, letter in its entirety with the revisions incorporated. Pursuant to section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product is now intended for the indications described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is included in the EUA Summary (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;

---

7 For ease of reference, this letter will use the term “you” and related terms to refer to LetsGetChecked, Inc.
8 The revisions to the May 19, 2021, letter and authorized labeling include: (1) update to the intended use to include pooling of up to five anterior nasal swab specimens, (2) update the home collection Instructions for Use with the revised intended use and other updates to reflect language used in more recent authorizations, (3) updates to the Healthcare Providers (HCP) and Individual Fact Sheets to include information on pooled specimens, and additional updates to reflect language used in more recent authorizations, and (4) updates to the Conditions of Authorization to include new conditions related to circulating variants (new conditions X and Y below) and new conditions related to pooling (new conditions Z, AA and BB below).
9 For ease of reference, this letter will use the term “your product” to refer to the LetsGetChecked Coronavirus (COVID-19) Test which is authorized for use as described in this letter with the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit, for the indication identified above.
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and,

3. There is no adequate, approved, and available alternative to the emergency use of your product.¹¹

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is a direct to consumer product for testing of anterior nasal swab specimens collected at home using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit by any individuals, age 18 years and older (self-collected), 12 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance), including individuals without symptoms or other reasons to suspect COVID-19.

Your product is also indicated for the qualitative detection of nucleic acid from SARS-CoV-2 in pooled samples containing up to 5 anterior nasal swab specimens per pool that were collected in individual vials containing transport media using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit from any individual (age 2 years and older), including individuals without symptoms or other reasons to suspect COVID-19.

Testing is limited to the LetsGetChecked, Inc. laboratory (PrivaPath Labs d.b.a. LetsGetChecked Labs) which is certified under CLIA and meets the requirements to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in anterior nasal swab specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 nucleic acid; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Specimens that are collected at home will not be tested with an internal control to confirm that the specimen was properly collected. Specimens collected at home from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly.

Negative results from pooled testing should not be treated as definitive. If a patient’s clinical signs and symptoms are inconsistent with a negative result and if results are necessary for patient management, then the patient should be considered for individual testing. Specimens included in

¹¹ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.
pools with a positive or invalid result must be tested individually prior to reporting a result. Specimens with low viral loads may not be detected in sample pools due to the decreased sensitivity of pooled testing.

Negative test results from specimens collected with the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit are delivered to the user via email, phone message and through an online portal. Individuals with positive and invalid results will be contacted by a healthcare provider. The direct to consumer home collection system is intended to enable users to access information about their COVID-19 status that could aid in determining if self-isolation or quarantine is appropriate and to assist with healthcare decisions after discussion with a healthcare provider.

Use of your product is not a substitute for visits to a healthcare provider. The information provided by this product should not be used to start, stop, or change any course of treatment unless advised by a healthcare provider.

Your product is an integrated nucleic acid testing system that fully automates all steps necessary to perform sample processing through amplification, detection, and data reduction. The assay incorporates an internal control, or other authorized control materials (as may be requested under Condition T below), to monitor nucleic acid capture, amplification, and detection, as well as operator or instrument error. To use your product, SARS-CoV-2 nucleic acid is first extracted, isolated and purified from anterior nasal swab specimens. All controls must generate expected results in order for a test to be considered valid, as outlined in the authorized procedures submitted as part of the EUA request.

Your product also requires the use of additional authorized materials and authorized ancillary reagents that are not included with your product and are described in the procedures submitted as part of the EUA request.


- Fact Sheet for Healthcare Providers: LetsGetChecked Inc. - LetsGetChecked Coronavirus (COVID-19) Test
- Fact Sheet for Individuals: LetsGetChecked Inc. - LetsGetChecked Coronavirus (COVID-19) Test

12 For this EUA, a healthcare provider includes any healthcare professional with prescribing abilities including, but not limited to, physicians, nurses, pharmacists, technologists, laboratory directors, and epidemiologists. The healthcare provider contacting individuals with test results will have prescribing privileges for that individual, should medication be indicated for treatment.
The LetsGetChecked Coronavirus (COVID-19) Home Collection Kit with the “LetsGetChecked Coronavirus (COVID-19) Home Collection Kit –Nasal Sample” collection instructions, LetsGetChecked Coronavirus (COVID-19) Home Collection Kit –Nasal Sample” box label, and Fact Sheet for Individuals is authorized to be distributed and used as set forth in this EUA.

The above described product, when accompanied by the authorized labeling as set forth in the Conditions of Authorization (Section IV), is authorized to be used by the authorized laboratory under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS’s corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

III. Waiver of Certain Requirements

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product.

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:
Let's Get Checked Inc. (You) and Authorized Distributor(s)\textsuperscript{13}

A. Your product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).

B. You and authorized distributor(s) must make available on your website(s), if applicable, the authorized Fact Sheet for Healthcare Providers.

C. You and authorized distributor(s) must make available all instructions related to the at home collection of anterior nasal swab specimens using the Let's Get Checked Coronavirus (COVID-19) Home Collection Kit and the Fact Sheet for Individuals both in the shipped kit and on your website(s).

D. Through a process of inventory control, you and authorized distributor(s) must maintain records of the numbers and locations to which the Let's Get Checked Coronavirus (COVID-19) Home Collection Kit is distributed.

E. You and authorized distributor(s) must maintain customer complaint files on record. You must report to FDA any significant complaints about usability or deviations from the established performance characteristics of the product of which you become aware.

F. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

G. You and authorized distributor(s) using your product must ensure that any records associated with this EUA, including test usage, are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

Let's Get Checked Inc. (You)

H. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).

I. You must provide authorized distributor(s) with a copy of this EUA and communicate any subsequent revisions that might be made to this EUA and its authorized accompanying materials.

J. You must inform relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product, or the authorized labeling.

\textsuperscript{13} "Authorized Distributor(s)" are identified by you, Let's Get Checked Inc., in your EUA submission as an entity allowed to distribute the Let's Get Checked Coronavirus (COVID-19) Home Collection Kit.
K. You must notify the relevant public health authorities of your intent to run your product.

L. You must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.

M. You must have a process in place for reporting all test results to individuals who use the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit. This process must include a requirement that all positive and invalid results must be reported to individuals who collected specimens at home using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit by a healthcare provider, defined in footnote 12. This process must ensure the Fact Sheet for Individuals is made available to individuals with the test result, for example via weblink.

N. You must require that entities\textsuperscript{14} using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit, acknowledge receipt of the following disclosure "Specimens that are collected at home will not be tested with an internal control to confirm that the specimen was properly collected. As such specimens collected at home from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly" that you must also include in test reports as required by Condition P. below.

O. You must include with result reports of your authorized test, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.

P. When testing authorized specimens collected at home using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit, you must include in the test report for specific patients whose specimen(s) were collected the following limitation: “Specimens that are collected at home were not tested with an internal control to confirm that the specimen was properly collected. As such, specimens collected at home from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly.”

Q. You must use your authorized test as outlined in the authorized test procedures submitted as part of the EUA request. Deviations from the authorized test procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and/or authorized materials required to use your product are not permitted.

R. When testing authorized specimens collected using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit you must follow the specimens accessioning protocol when accepting specimens for testing.

\textsuperscript{14} As used in this condition, “entities” refers to any organization that contracts with you to conduct testing (i.e., employers who are doing back to work testing, universities, hospitals, healthcare systems, etc.).
S. You must collect information on the performance of your product. You will report to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) (via email: CDRH-EUA-Reporting@fda.hhs.gov) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your authorized test of which you become aware.

T. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling. Any request for changes to this EUA should be submitted to DMD/OHT7-OIR/OPEQ/CDRH, and require appropriate authorization from FDA prior to implementation.

U. You must evaluate the analytical limit of detection and assess traceability of your product with any FDA-recommended reference material(s). After submission to and concurrence with the data by FDA, you will update your labeling to reflect the additional testing. Such labeling updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

V. You must have a process in place to track adverse events, including any occurrence of false results with your product, including the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit, in accordance with 21 CFR Part 803. Serious adverse events, especially unexpected biosafety concerns, should immediately be reported to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov).

W. All laboratory personnel using your product must be appropriately trained in molecular techniques and use appropriate laboratory and personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.

X. You must evaluate the impact of SARS-CoV-2 viral mutations on your product’s performance. Such evaluations must occur on an ongoing basis and must include any additional data analysis that is requested by FDA in response to any performance concerns you or FDA identify during routine evaluation. Additionally, if requested by FDA, you must submit records of these evaluations for FDA review within 48 hours of the request. If your evaluation identifies viral mutations that affect the stated expected performance of your device, you must notify FDA immediately.

Y. If requested by FDA, you must update your labeling within 7 calendar days to include any additional labeling risk mitigations identified by FDA, such as those related to the impact of viral mutations on test performance. Such updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

Z. When using specimen pooling strategies when testing patient specimens with your product, you must include with negative test result reports for specific patients whose specimen(s) were the subject of pooling, a notice that pooling was used during testing.

---

15 Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material.
and that, “Patient specimens with low viral loads may not be detected in sample pools due to the decreased sensitivity of pooled testing.”

AA. When using specimen pooling strategies for testing patient specimens you must use the Specimen Pooling Implementation and Monitoring Guidelines provided in the authorized labeling to evaluate the appropriateness of continuing to use such strategies based on the recommendations in the protocol.

BB. You must keep records of specimen pooling strategies implemented including the type of strategy, date implemented, and quantities tested, and test result data generated as part of the Specimen Pooling Implementation and Monitoring Guidelines provided in the authorized labeling. For the first 12 months from the date of their creation, such records must be made available to FDA within 48 business hours for inspection upon request. After 12 months from the date of their creation, upon FDA’s request such records must be made available for inspection within a reasonable time.

Conditions Related to Printed Materials, Advertising and Promotion

CC. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and meet the applicable requirements set forth in section 502(a), (q)(1), and (r) of the Act, as applicable, and FDA implementing regulations.

DD. No descriptive printed matter, advertising, or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.

EE. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

V. Duration of Authorization
This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

____________________________
RADM Denise M. Hinton
Chief Scientist
Food and Drug Administration

Enclosure